Short answer
TransMedics Group, Inc. (TMDX) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 results covered quarter ended March 31, 2026.
TransMedics Group, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 results covered quarter ended March 31, 2026
- Earnings press release issued May 5, 2026
- Detailed financial results available in Exhibit 99.1
- Information furnished, not filed under Exchange Act Section 18 liability provisions
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $173.9M, up 21% YoY, driven by higher OCS utilization and logistics services
- Profitability weakened: gross margin 58% vs 61%, operating margin 7.6% vs 19.1%
- Operating expenses rose to $87.9M from $60.8M, reflecting higher R&D and growth investments
- Net income fell to $7.3M, or $0.20 per diluted share, from $25.7M and $0.70
- FY2026 revenue guidance reiterated at $727M-$757M, implying 20%-25% growth; cash totaled $461.7M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other TransMedics Group, Inc. 8-K filings
Get the next TMDX 8-K as it lands
Follow TMDX for push alerts, or ask the research agent what this filing means.